Eli Lilly and Company scores 39/100 (Below expectations) on SINK's independent climate assessment — scored from public data only, no company payment can change a number. Last verified May 2026.
That places Eli Lilly and Company joint 376th of 809 companies scored, and joint 12th of 15 in Healthcare / Pharmaceuticals.
Eli Lilly has renewable energy momentum but weak climate fundamentals. Scope 1 emissions rose 5.5% in 2024 despite carbon neutrality claims. No SBTi targets, no Scope 3 reduction plans, and active trade association opposition to climate policy undermine credibility. Greenwashing risk is material.
Every supplier scored from public evidence like this, ranked, in 48 hours. No questionnaires, and your suppliers never know.
This score uses public evidence only. Challenge any question for free, or ask for a human review of evidence you haven't published.
Same ten questions for every company. No private weighting.
SINK = (0.3 × Base + 0.7 × Performance) × ScaleStrongest on Carbon Footprint — Operations and Carbon Footprint — Supply Chain (7/10, 6/10). Weakest on Controversies & Red Flags and Targets & Commitments (1/10, 3/10).
15 sources used in this assessment. All publicly available. Each row shows which rubric questions it informed.
8 of 15 sources are third-party verified or public record.
If you believe a source has been misread or a newer version exists, submit a challenge.
Eli Lilly and Company is tied at the bottom of the healthcare / pharmaceuticals pack.
Among the 15 major healthcare / pharmaceuticals brands we've scored, Eli Lilly and Company is tied =12th of 15, with 3 others.
Score history begins 4 April 2026.
As Eli Lilly and Company's score updates, the trajectory will appear here.
This score is not currently being contested.
Every challenge is published. We'd rather be corrected than wrong — that's the whole point.
No challenges submitted yet. If you have evidence that contradicts this score, you can challenge any question above — cite a public source and we'll review it.
Eli Lilly is a $45B US pharmaceutical company headquartered in Indianapolis, founded in 1876. A major player in therapeutics, vaccines, and animal health, the company manufactures across global sites and sources from complex supply chains. It operates in a sector facing rising scrutiny over environmental impact and access to medicines.
Pharmaceutical peer with similar scale and trade association exposure; baseline for sector comparison.
View breakdown →Large pharma comparable on emissions scope and renewable energy adoption; different SBTi commitment status.
View breakdown →Pharma competitor with published Net Zero strategy; useful contrast on Scope 3 target depth.
View breakdown →Healthcare conglomerate with broader ESG reporting; similar lobbying exposure patterns.
View breakdown →Email alerts when a rubric question is verified, a challenge is resolved, or the overall score changes.
One email, every Sunday. Score changes, new research, the stories behind the numbers. Free.
No spam. Unsubscribe in one click.
Checking a company?
Search free →Checking your suppliers?
Get your list scored in 48 hours →Been scored?
See what's behind your number →Nobody can pay us to change a number.